InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

Current share price for OCC : $0.770 0.025 (3.14%)+

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$208 Q4 FY26 ASX Investor Presentation 14 Jul 2026 8:47AM $0.850 $0.765 fallen by 10%
$208 Quarterly Activity Report & Appendix 4C 13 Jul 2026 8:53AM $0.845 $0.765 fallen by 9.47%
$208 Orthocell Investor Webinar Details 6 Jul 2026 8:43AM $0.755 $0.765 risen by 1.32%
$208 Orthocell Appoints Thailand Distributor for Remplir 3 Jul 2026 8:56AM $0.720 $0.765 risen by 6.25%
$208 Clinical Outcomes See Expanded Use of Remplir in the Ukraine 30 Jun 2026 8:51AM $0.725 $0.765 risen by 5.52%
$208 Cleansing Notice 14 May 2026 4:15PM $0.830 $0.765 fallen by 7.83%
$208 Application for quotation of securities - OCC 14 May 2026 4:11PM $0.830 $0.765 fallen by 7.83%
$208 Cleansing Notice 5 May 2026 4:22PM $0.855 $0.765 fallen by 10.53%
$208 Application for quotation of securities - OCC 5 May 2026 4:19PM $0.855 $0.765 fallen by 10.53%
$208 Appendix 3Y - Michael McNulty 4 May 2026 9:39AM $0.900 $0.765 fallen by 15%
$208 Appendix 3Y - John Van Der Wielen 4 May 2026 9:36AM $0.900 $0.765 fallen by 15%
$208 First Sales of Remplir Achieved in US$75m Canadian Market 30 Apr 2026 9:14AM $0.880 $0.765 fallen by 13.07%
$208 Compelling 90% Success Rate for Remplir in Real World Study 28 Apr 2026 9:10AM $0.850 $0.765 fallen by 10%
$208 Q3 FY26 Investor Presentation 20 Apr 2026 9:05AM $1.035 $0.765 fallen by 26.09%
$208 Quarterly Activity Report & Appendix 4C 20 Apr 2026 9:04AM $1.035 $0.765 fallen by 26.09%
$208 First Surgical Use of Remplir in US Department of Defense 17 Apr 2026 9:01AM $1.020 $0.765 fallen by 25%
$208 OCC Secures Access to 221 U.S. Military Medical Centres 15 Apr 2026 9:00AM $0.870 $0.765 fallen by 12.07%
$208 Notification of cessation of securities - OCC 15 Apr 2026 8:25AM $0.870 $0.765 fallen by 12.07%
$208 Orthocell Investor Webinar Details 14 Apr 2026 10:20AM $0.865 $0.765 fallen by 11.56%
$208 US Section 232 Tariffs Not Expected to Affect Remplir 8 Apr 2026 9:06AM $0.760 $0.765 risen by 0.66%
$208 Orthocell Investor Presentation - Broker Meets Biotech 31 Mar 2026 2:43PM $0.765 $0.765 fallen by 0%
$208 Remplir Used in 23 Surgeries in Ukrainian soldiers 18 Mar 2026 9:57AM $0.780 $0.765 fallen by 1.92%
$208 Notification of cessation of securities - OCC 16 Mar 2026 7:29PM $0.785 $0.765 fallen by 2.55%
$208 Notification regarding unquoted securities - OCC 16 Mar 2026 6:34PM $0.785 $0.765 fallen by 2.55%
$208 Orthocell Appoints UK Distributor for Remplir 10 Mar 2026 9:08AM $0.800 $0.765 fallen by 4.38%

1 - 25 of 750 results

Page 1 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.